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Abstract
Background: Previous health economic studies recommend either a dual screening strategy [tuberculin skin test
(TST) followed by interferon-g-release assay (IGRA)] or a single one [IGRA only] for latent tuberculosis infection
(LTBI), the former largely based on claims that it is more cost-effective. We sought to examine that conclusion
through the use of a model that accounts for the additional costs of adverse drug reactions and directly compares
two commercially available versions of the IGRA: the Quantiferon-TB-Gold-In-Tube (QFT-GIT) and T-SPOT.TB.
Methods: A LTBI screening model directed at screening contacts was used to perform a cost-effectiveness analysis,
from a UK healthcare perspective, taking into account the risk of isoniazid-related hepatotoxicity and post-exposure
TB (2 years post contact) using the TST, QFT-GIT and T-SPOT.TB IGRAs.
Results: Examining costs alone, the TST/IGRA dual screening strategies (TST/T-SPOT.TB and TST/QFT-GIT; £162,387
and £157,048 per 1000 contacts, respectively) cost less than their single strategy counterparts (T-SPOT.TB and
QFT-GIT; £203,983 and £202,921 per 1000 contacts) which have higher IGRA test costs and greater numbers of
persons undergoing LTBI treatment. However, IGRA alone strategies direct healthcare interventions and costs more
accurately to those that are truly infected.
Subsequently, less contacts need to be treated to prevent an active case of TB (T-SPOT.TB and QFT-GIT; 61.7 and
69.7 contacts) in IGRA alone strategies. IGRA single strategies also prevent more cases of post-exposure TB. How-
ever, this greater effectiveness does not outweigh the lower incremental costs associated with the dual strategies.
Consequently, when these costs are combined with effectiveness, the IGRA dual strategies are more cost-effective
than their single strategy counterparts. Comparing between the IGRAs, T-SPOT.TB-based strategies (single and dual;
£39,712 and £37,206 per active TB case prevented, respectively) were more cost-effective than the QFT-GIT-based
strategies (single and dual; £42,051 and £37,699 per active TB case prevented, respectively). Using the TST alone
was the least cost-effective (£47,840 per active TB case prevented). Cost effectiveness values were sensitive to
changes in LTBI prevalence, IGRA test sensitivities/specificities and IGRA test costs.
Conclusion: A dual strategy is more cost effective than a single strategy but this conclusion is sensitive to
screening test assumptions and LTBI prevalence.
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Identification and treatment of latent tuberculosis cases
remains an effective strategy in the control of tuberculo-
sis (TB). The tuberculin skin test (TST) has been the
primary tool for identifying these individuals. However,
the recently introduced interferon-gamma release assays
(IGRAs), which measure IFN-g responses to the rela-
tively TB-specific antigens ESAT-6 and CFP-10, have
been gaining acceptance in the past few years as poten-
tial replacements for the TST. In low burden settings
IGRAs correlate better with exposure to M. tuberculosis
than TST (reviewed in [1-3]) and are more specific in
BCG-vaccinated subjects [4], particularly when BCG is
given after infancy [5].
Two versions of the IGRA are now commercially
available: The T-SPOT®.TB (Oxford Immunotec Ltd,
Oxford, UK) and Quantiferon®-TB Gold In-tube (Celles-
tis Ltd., Carnegie, Australia), which use an ELISPOT
and ELISA format, respectively. While both have
improved performance characteristics over the TST in
low burden settings, T-SPOT.TB may be more sensitive
and associated with less indeterminate results, especially
in an immunocompromised population [2,6].
Varying guidelines on the application of these assays
have been published [7,8]. The Centers for Disease Con-
trol and Prevention, USA, recommends that IGRA can
replace TST in all settings [8]. By contrast, in the UK, the
National Institute of Health and Clinical Excellence
(NICE) recommends the use of IGRAs using a dual testing
strategy, where IGRA is only performed on individuals
who have a positive TST result [7]. Several other countries
have adopted a similar approach (e.g. France, Canada).
These considerations are based mainly on cost effective-
ness calculations. We sought to re-examine this choice as
the NICE analysis [7] was based on only limited data
about the IGRAs. Since then only a limited number of
independent cost-analyses have been performed [9-16]
and none have directly compared the cost effectiveness of
screening with both standardized versions of the IGRAs.
Furthermore, none of these subsequent studies have been
performed in the UK, where healthcare costs may be dif-
ferent to those in other European countries, costs related
to post-exposure TB were not included in some models
[13,14], and only half of these studies [11,15,16] take into
account the effect of isoniazid-induced hepatotoxicity.
Whilst uncommon (~0.1% to 0.6%), this adverse drug-
reaction may be costly to treat and even fatal [17].
In this study, a decision tree was constructed to mea-
sure the costs and clinical outcomes (i.e. effectiveness)
over a 2 year period of screening a cohort of 1,000 indi-
viduals, from a UK healthcare perspective, using either a
single (TST or IGRA) or dual (TST followed by IGRA)
strategy. Both versions of the IGRA (T-SPOT.TB and
QFT-GIT) were evaluated in the analysis. The base case
of the analysis was chosen to represent a cohort of close
contacts of infectious TB cases, but the variation of the
parameters in the sensitivity analysis allows some con-
clusions to be drawn about cohorts with differing
epidemiology.
Methods
Model Structure
A decision tree was used to represent the clinical path-
ways associated with screening close contacts of infec-
tious TB index cases. Five different screening scenarios
were investigated in this cost-effectiveness analysis: (1)
TST alone, (2) the T-SPOT.TB assay alone, (3) TST fol-
lowed by T-SPOT.TB assay when TST was positive
(TST/T-SPOT.TB), (4) Quantiferon-TB-Gold-In-Tube
(QFT-GIT) alone, and (5) TST followed by QFT-GIT
when TST was positive (TST/QFT-GIT). Construction
of the decision tree and analysis was performed using
TreeAge Pro 2009 (TreeAge Software Inc., Williamston,
MA, USA) and Microsoft Excel 2003 (Microsoft, USA).
Decision trees are shown in figures 1, 2 and 3. See addi-
tional file 1: supplemental data for a description of the
decision tree models. No ethical approval was required
for this study.
Model Parameters
Probability values were sourced from published litera-
ture. Cost estimates were taken from UK national
sources or from published literature when data from
these sources were unavailable. All costs were updated
to 2008 GBP using the Bank of England Consumer
Price Index [18]. There was no time discounting of
future costs as the time period of the model was only 2
years. All costs and probabilities are shown in table 1.
See additional file 1: supplemental data for details of the
model parameters.
Effectiveness Measures
The number of active TB cases prevented and the num-
ber-needed-to treat (NNT) i.e. the number of people
treated for LTBI to prevent an active TB case was calcu-
lated for each strategy. Cost-effectiveness was measured
as the total cost per active TB case prevented and the
incremental cost per active TB case prevented. See addi-
tional file 1: supplemental data for details on how these
measures were calculated.
Model Assumptions
(i) All contacts who may already have active TB would
be symptomatic and be identified at initial clinical
examination (approximately 1% of contacts have active
TB on initial screening [19]). We acknowledge the
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have active disease, but be asymptomatic, and would
therefore be missed at the time of initial examination.
Therefore, we assume there are no active cases at the
time of testing. (ii) Close contact with an infectious TB
case in association with laboratory evidence of latent
tuberculosis infection (LTBI) is an indication for LTBI
preventative treatment in the UK. Therefore, it is
assumed that the test (either IGRA or TST) result is the
only indicator for LTBI and treatment is given solely
based on this assumption. (iii) As there is no gold-stan-
dard for LTBI detection, test sensitivities and specifici-
ties were obtained from confirmed TB cases and healthy
contacts at low risk for exposure, respectively (iv) We
assume that isoniazid treatment will cease if severe
drug-induced hepatitis develops, while mild rises in
transaminase levels would result in continued usage
with monitoring of liver function tests, or substitution
with another drug (ethambutol or rifampicin) at no
extra cost [19-21]. We assumed that hepatitis would
develop in the first three months of treatment [22,23].
In order to keep the model simple, we assigned a treat-
ment stop-point of 3 months, as assumed in other cost
analyses [11,15]. Therefore, a person developing severe
hepatitis will only receive a 3 month course of isoniazid,
which provides only partial protection. Conversely, a
person who does not develop hepatitis will receive a full
6 months isoniazid (recommended in the UK in contrast
to 9 months in the USA) and will benefit from better
protection [24]. (v) The model only examines post-expo-
sure cases of TB occurring within a 2 year period, and
also does not take into account further spread of TB
into the population. It also assumes that following che-
moprevention, individuals do not become re-infected.
Results
Base case analysis
Cost and probability estimates were inputted into the
decision tree model to determine associated costs and
effectiveness measures of each screening strategy. Total
and component costs for the base case are shown in
table 2. In costs terms alone, the two IGRA single
screening strategies were the most expensive, with the
T-SPOT.TB and the QFT-GIT almost identical in over-
all cost at £203,983 and £202,921 per 1000 contacts
screened, respectively. Test costs comprised a significant
Figure 1 TST screening strategy for diagnosis of presumed latent TB infection (LTBI). A decision tree for the diagnosis of LTBI using the
TST alone in a single test strategy. Square nodes represent decision branches, circular nodes represent chance branches and triangular nodes
represent terminal branches.
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gies. Conversely, the TST/QFT-GIT and TST/T-SPOT.
TB dual strategies were the least costly at £157,048 and
£162,387 per 1000 contacts screened, respectively. How-
ever, the breakdown of where those costs go is reveal-
ing. The dual strategies had higher costs resulting from
false negative results due to the combination of false
negative TST and IGRA results. The TST alone strategy
(£199,589 per 1000 contacts) had the lowest test costs
(£15,433) but this strategy incurred the highest costs
resulting from test inaccuracies (£70,081), particularly
the costs incurred on false positive results (£55,090). If
no screening is performed, then this still incurs down-
stream costs due to the treatment of resulting active TB
cases; this amounts to £57,148 per 1000 contacts over
the 2 year period of the model.
Table 3 shows the effectiveness measures of each
screening strategy. While the single IGRA screening
strategies were the most costly, they were also the most
effective at preventing cases of post-primary TB. Com-
pared to conducting no screening, the T-SPOT.TB
alone prevented 3.7 cases per 1000 contacts screened
while the QFT-GIT prevented 3.47 cases per 1000 con-
tacts screened. The dual strategies (TST/QFT-GIT and
TST/T-SPOT.TB) resulted in the most post-primary TB
cases occurring for the 2 year time frame (4.85 and 4.67
per 1000 contacts screened, respectively) and subse-
quently prevented the lowest number of TB cases (2.65
and 2.83 per 1000 contacts, respectively). The TST was
the least effective of the single screening strategies (but
more effective than the dual strategies), averting 2.98
cases of TB out of 1000 screened contacts. Another
measure of effectiveness calculated was the number-
needed-to-treat (NNT) i.e. the number of contacts trea-
ted for LTBI to prevent a case of active TB. Of the 1000
contacts screened using the TST alone strategy, 284
contacts were treated for LTBI resulting in an NNT of
95.5. This was the highest of all the strategies due to the
large number of false positive that were given LTBI
treatment (101 contacts). The T-SPOT.TB single and
dual strategies had the lowest NNT of all the strategies
(61.7 contacts). The QFT-GIT strategies were somewhat
less efficient with an NNT of 69.7 and 63.6 for the sin-
gle and dual strategies respectively.
Table 4 shows the cost effectiveness measures of each
strategy. Cost effectiveness of each strategy was given as
the incremental cost per active TB case prevented which
represents the additional cost of a strategy over the
baseline cost of not screening. TSPOT.TB dual screen-
ing was the most cost effective strategy costing £37,206
Figure 2 IGRA (T-SPOT.TB or QFT-GIT) screening strategy for diagnosis of presumed latent TB infection (LTBI). A decision tree for the
diagnosis of LTBI using the IGRA (T-SPOT.TB or QFT-GIT) alone in a single test strategy. Square nodes represent decision branches, circular nodes
represent chance branches and triangular nodes represent terminal branches. The same decision tree was used for both versions of IGRA single
strategies as they both have identical screening steps in each scenario.
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dual screening strategy (£37,699 per active TB case pre-
vented). The IGRA single strategies were the next most
cost effective options (T-SPOT.TB and QFT-GIT;
£39,712 and £42,051 per case of active TB prevented,
respectively). In both versions of the IGRA, dual screen-
ing was more cost effective than single screening; TST/
T-SPOT.TB was £2,506 better than the T-SPOT.TB sin-
gle strategy and TST/QFT-GIT was £4,351 better than
screening with QFT-GIT only. T-SPOT.TB based strate-
gies were also more cost effective than QFT-GIT based
strategies. Screening with the TST alone remained the
least cost effective strategy at £47, 840 incremental cost
per case of active TB prevented.
Different results were produced when total cost per
active TB case prevented of each strategy was calculated
based on the total costs of each strategy (rather than
incremental costs). Using this measure, IGRA single
strategies were actually found to be more cost effective
than their dual strategy counterparts. The T-SPOT.TB
alone was the most cost effective strategy costing
£55,168 per active TB case prevented. The T-SPOT.TB
dual strategy (£57,410 per active TB case prevented) was
the next best from a cost effectiveness standpoint, fol-
lowed by the QFT-GIT single and dual strategies
(£58,536 and £59,265 per active TB cases prevented
respectively). The TST alone was still the least cost
effective option (£67,034 per active TB case prevented).
Sensitivity analysis
Univariate deterministic sensitivity analysis identified a
range of possible cost effectiveness outcomes, in terms
of the incremental cost per case of active TB, for all
variables (table 5 and 6). In most cases, when variables
were changed within their specified ranges, T-SPOT.TB
dual screening was the most cost effective strategy while
screening with the TST alone was the least cost effective
strategy.
Changing LTBI prevalence had a significant impact on
overall cost effectiveness. At the lower prevalence esti-
mate (10%), cost effectiveness values significantly
increased due to screening preventing less downstream
cases of active TB (this is logical as, in extremis,s c r e e n -
ing a population with no infection is completely
Figure 3 Dual screening strategy (IGRA on all TST positive) for diagnosis of presumed latent TB infection (LTBI). Decision tree for the
diagnosis of LTBI using a dual diagnostic strategy (TST in all cases followed by the T-SPOT.TB or QFT-GIT for a positive TST result). Square nodes
represent decision branches, circular nodes represent chance branches and triangular nodes represent terminal branches. The same decision tree
was used for both versions of the IGRA dual strategy as they both have identical screening steps in each scenario.
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Variable Baseline Range Source
Probabilities
Prevalence of LTBI 0.30 0.1-0.4 [24,39,40]
TST return rate 0.90 0.65-0.95 [14,27]
T-SPOT.TB sensitivity 0.95 0.83-0.97 [30,41-43]
T-SPOT.TB specificity 1.00 0.92-0.99 [41,43]
T-SPOT.TB positive result 0.285 Calculated
T-SPOT.TB true positive (PPV) 1.000 Calculated
T-SPOT.TB true negative (NPV) 0.979 Calculated
T-SPOT.TB true positive (PPV) given a positive TST 1.000 Calculated
T-SPOT.TB negative (NPV) given a positive TST 0.987 Calculated
QFT-GIT sensitivity 0.89 0.85-0.95 [32,44]
QFT-GIT specificity 0.95 0.90-0.97 [32,44]
QFT-GIT positive result 0.302 Calculated
QFT-GIT true positive (PPV) 0.884 Calculated
QFT-GIT true negative (NPV) 0.953 Calculated
QFT-GIT true positive (PPV) given a positive TST 0.930 Calculated
QFT-GIT true negative (NPV) given a positive TST 0.971 Calculated
TST sensitivity 0.85 0.69-0.95 [30,41,42,45]
TST specificity 0.80 0.65-0.90 [20,46]
TST positive result 0.395 Calculated
TST true positive (PPV) 0.646 Calculated
TST true negative (NPV) 0.926 Calculated
Start INH treatment 0.80 0.55-0.95 [47]
Develop severe INH hepatitis 0.003 0.003-0.041 [47-50]
Death due to hepatitis 0.00002 0.00001-0.0001 [51,52]
Efficacy of 3 months INH (LTBI fully cured) 0.21 0.1-0.3 [23,24,53]
LTBI not cured (with 3 months INH) 0.79 0.7-0.9 [23,24,53]
Efficacy of 6 months INH (LTBI fully cured) 0.65 0.5-0.93 [10,17,23,49,53,54]
LTBI not cured (with 6 months INH) 0.35 0.07-0.5 [10,17,23,49,53]
Post exposure TB 0.025 0.01-0.05 [14,55]
TB remains latent 0.975 0.95-0.99 [14,55]
Cost (British Pounds; £s)
T-SPOT.TB (kit, consumables and processing) +
phlebotomy
55.00 45.00-100.00 Test cost from Royal Free Hospital, London;
Phlebotomy cost from [56]
TST(cost of disposables, administration and reading) 16.14 8.07-32.28 [7,18,57]
QFT-GIT (kit, consumables and processing) +
phlebotomy
45.00 35.00-80.00 Test cost from Royal Blackburn Hospital;
Phlebotomy cost from [56]
Treatment for severe INH hepatotoxicity 629.12 314.56-1258.24 [18,20,56]
3 months INH treatment 484.38 242.19-968.76 Calculated from [7,18]
6 months INH treatment 524.59 262.30-1049.18 [7,18]
Treatment for active TB 7619.67 3809.84-15239.34 [18,37]
(LTBI-latent tuberculosis infection, TST-Tuberculin Skin Test, INH-isoniazid, PPV-positive predictive value, NPV-negative predictive value).
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each strategy becoming more cost effective compared to
the base-case estimates due to the prevention of greater
numbers of future active TB cases. However cost effec-
tiveness (CE) rankings did not change within the para-
meters of the sensitivity analysis.
In our model, test sensitivities and specificities were
varied according to the range of values reported in the
literature. A lower test sensitivity (TST, QFT-GIT or
T-SPOT.TB) reduces the cost of that strategy as fewer
cases of true LTBI are detected and treated. However,
these missed LTBI cases result in a greater number of
post-primary TB cases for the 2 year screening period.
As a result, lowering test sensitivity decreases the cost
effectiveness of that strategy. CE rankings changed in
favour of the QFT-GIT based strategies only if
QFT-GIT sensitivity is ~8% higher than T-SPOT.TB
sensitivity. Similarly, screening with TST only becomes
more cost-effective than both IGRA test options (QFT-
GIT or T-SPOT.TB single and dual) if the sensitivity of
the TST is ~38% more than the sensitivity of T-SPOT.
TB and ~40% greater than the sensitivity of QFT-GIT.
The strategy with a less specific test will cost more
due to greater treatment and follow-up costs arising
from false positive diagnoses without changing effective-
ness measures in the model. Thus, lowering test specifi-
city decreases the cost effectiveness of a particular
strategy. Reducing T-SPOT.TB specificity to 92% makes
the QFT-GIT dual strategy (£37,699 per active TB case
prevented) more cost effective than the T-SPOT.TB
dual strategy (£38,707 per active TB case prevented).
The T-SPOT.TB single strategy became the least cost-
effective when T-SPOT.TB specificity fell below 85%, all
other things being equal. Lowering QFT-GIT specificity
to the lower limit of the sensitivity analysis does not
change the CE rankings. QFT-GIT-based strategies
Table 2 Analysis of costs of each screening strategy
Cost Measures TST T-SPOT.TB QFT-GIT TST/T-SPOT.TB TST/QFT-GIT No screening
Treatment & follow-up costs £184,156 £148,983 £157,921 £127,402 £125,618 £57,148
Test costs £15,433 £55,000 £45,000 £34,986 £31,431 £0
Total costs £199,589 £203,983 £202,921 £162,387 £157,048 £57,148
Breakdown of costs associated with test inaccuracies
Costs incurred on false positives £55,090 £0 £16,313 £0 £3,038 -
Costs incurred on false negatives £8,369 £3,682 £7,771 £11,371 £14,721 -
Costs incurred on TST non-returns £6,622 £0 £0 £6,622 £6,622 -
All costs are expressed in British pounds (£). Costs relate to outcomes and costs for entire cohort of 1,000 contacts over the 2 year examination period.
(TST - Tuberculin Skin Test, QFT-GIT - Quantiferon-TB Gold-In-Tube)
Table 3 Analysis of effectiveness of each screening strategy
Effectiveness Measures TST T-SPOT.TB QFT-GIT TST/T-SPOT.TB TST/QFT-GIT
Numbers of post-primary TB cases in 2 year period 4.52 3.80 4.03 4.67 4.85
Number of TB cases prevented by screening strategy 2.98 3.70 3.47 2.83 2.65
Numbers of people treated for LTBI 284 228 242 174 168
Numbers of true positives treated 184 228 214 174 163
Numbers of false positives treated 101 0 28 0 5
Numbers of people treated for LTBI per case of active TB prevented (NNT) 95.5 61.7 69.7 61.7 63.6
Effectiveness measures relate to outcomes and costs for entire cohort of 1,000 contacts over the 2 year examination period. No screening results in 7.5 cases of
post-primary TB in the 2 year period. (TST - Tuberculin Skin Test, QFT-GIT - Quantiferon-TB Gold-In-Tube, NNT- number needed to treat)
Table 4 Analysis of cost-effectiveness of each screening strategy
Cost-effectiveness Measures TST T-SPOT.TB QFT-GIT TST/T-SPOT.TB TST/QFT-GIT
Total costs of screening £199,589 £203,983 £202,921 £162,387 £157,048
Incremental cost of screening (compared to no screening) £142,442 £146,836 £145,774 £105,240 £99,901
Active TB cases prevented 2.98 3.70 3.47 2.83 2.65
Cost per active TB case prevented £67,034 £55,168 £58,536 £57,410 £59,265
Incremental cost per active case prevented (compared to no screening) £47,840 £39,712 £42,051 £37,206 £37,699
Savings per active TB case prevented (compared to TST) - £8,128 £5,790 £10,634 £10,141
All costs are expressed in British pounds (£). Cost-effectiveness relates to outcomes and costs for entire cohort of 1,000 contacts over the 2 year examination
period. (TST - Tuberculin Skin Test, QFT-GIT - Quantiferon-TB Gold-In-Tube)
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strategies if QFT-GIT specificity is within ~1% of T-
SPOT.TB specificity. TST only screening becomes more
cost-effective than either IGRA single strategy if TST
specificity is within ~6% of T-SPOT.TB or QFT-GIT
specificity.
Greater efficacy of a 6 month course of INH improved
the overall cost effectiveness of the screening strategies, as
more persons are successfully cured of LTBI. If efficacy
was increased to 93%, the CE ranking remained consistent
but the incremental cost per active TB case prevented for
each strategy decreased by approximately £15,000 per
1000 contacts screened compared to base-case estimates.
At lower TST return rates, dual (TST/QFT-GIT and
TST/T-SPOT.TB) and TST alone strategy costs decrease
as fewer LTBI individuals are identified and treated. How-
ever, more TST non-returners would progress to post pri-
mary TB in the two year time frame. As a result, cost
Table 5 Cost-effectiveness of screening strategies when probabilities are varied in the sensitivity analysis.
Probability Variable Incremental cost per Active TB case prevented (British Pounds; £’s)
TST T-SPOT.TB QFT-GIT TST/T-SPOT.TB TST/QFT-GIT
Base-case estimates £47,840
5# £39,712
3 £42,051
4 £37,206
1 £37,699
2
Prevalence
0.1 £109,120
5 £69,462
3 £80,160
4 £55,118
1 £58,321
2
0.4 £40,180
5 £35,994
3 £37,287
4 £34,967
1 £35,122
2
T-SPOT.TBsensitivity
0.83 £47,840
5 £41,863
3 £42,051
4 £38,994
2 £37,699
1
0.97 £47,840
5 £39,406
3 £42,051
4 £36,951
1 £37,699
2
T-SPOT.TBspecificity
0.92 £47,840
5 £46,090
4 £42,051
3 £38,707
2 £37,699
1
0.99 £47,840
5 £40,510
3 £42,051
4 £37,394
1 £37,699
2
QFT-GIT sensitivity
0.85 £47,840
5 £39,712
3 £42,862
4 £37,206
1 £38,305
2
0.95 £47,840
5 £39,712
3 £40,962
4 £37,206
2 £36,887
1
QFT-GIT specificity
0.9 £47,840
5 £39,712
3 £46,302
4 £37,206
1 £38,701
2
0.97 £47,840
5 £39,712
3 £40,350
4 £37,206
1 £37,299
2
TST sensitivity
0.69 £53,174
5 £39,712
2 £42,051
4 £39,039
1 £39,778
3
0.95 £45,419
5 £39,712
3 £42,051
4 £36,374
1 £36,756
2
TST specificity
0.65 £61,205
5 £39,712
2 £42,051
4 £39,044
1 £40,055
3
0.9 £38,931
3 £39,712
4 £42,051
5 £35,981
1 £36,129
2
Starting LTBI treatment
0.55 £50,196
5 £46,474
3 £47,951
4 £42,828
1 £43,091
2
0.95 £47,022
5 £37,364
3 £40,001
4 £35,253
1 £35,827
2
Severe INH hepatitis
0.001 £47,653
5 £39,576
3 £41,923
4 £37,073
1 £37,563
2
0.023 £49,743
5 £41,100
3 £43,341
4 £38,559
1 £39,082
2
Efficacy of 6 months INH treatment
0.5 £64,457
5 £53,894
3 £56,918
4 £50,637
1 £51,278
2
0.93 £31,154
5 £25,472
3 £27,114
4 £23,719
1 £24,064
2
TST return rate
0.95 £47,680
5 £39,712
3 £42,051
4 £37,037
1 £37,519
2
0.65 £49,012
5 £39,712
3 £42,051
4 £38,439
1 £39,016
2
Post exposure TB
0.01 £52,412
5 £44,284
3 £46,619
4 £41,778
1 £42,271
2
0.05 £40,221
5 £32,093
3 £34,437
4 £29,586
1 £30,080
2
# The superscripts
1-5 indicate the cost-effectiveness ranking;
(1) indicates most cost effective strategy while
(5) indicates the least cost-effective strategy. (LTBI -
latent tuberculosis infection, TST - tuberculin skin test, INH - isoniazid, QFT-GIT - Quantiferon-TB Gold-In-Tube)
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Page 8 of 14effectiveness of these strategies is reduced. At 65% return
rate, CE ranking remained consistent. However, T-SPOT.
TB or QFT-GIT dual strategies became less cost effective
than their single strategy counterparts when the TST
return rate was ≤ 50% and ≤ 39%, respectively.
The incidence of post exposure TB did not significantly
impact the cost effectiveness of the screening strategies.
Different estimates of post exposure TB incidence not
only changed overall costs and effectiveness measures of
each strategy but also those of the ‘no screening’ sce-
nario. As a result, the incremental cost per case of active
TB prevented did not dramatically change. At a 1% inci-
dence over 2 years, the incremental cost per case of
active TB prevented increased by ~£5,000, compared to
base-case estimates. The reverse occurred when the rate
of post exposure TB was 5% i.e. incremental cost per
active TB case prevented decreased by ~£5,000. The CE
rankings remained consistent in each case.
Varying test costs and LTBI treatment costs had the
greatest impact on cost effectiveness. When IGRA test
costs were increased to the upper limit of the sensitivity
analysis estimate, the gap in cost-effectiveness between
IGRA single strategies and their dual strategy counter-
parts widened. However, all IGRA strategies (single and
dual) still remained more cost effective than the TST
alone option. Only when T-SPOT.TB and QFT-GIT
costs were increased to ≥ £140 and ≥ £121 did the TST
become the most cost effective option.
A 50% reduction in LTBI treatment costs reduced the
incremental cost per case of active TB prevented for
each strategy compared to the base-case analysis. The
CE rankings also changed so that the TST became more
cost effective than both IGRA single strategies. However
the IGRA dual strategies remained the most cost effec-
tive. Doubling LTBI treatment costs almost doubled
incremental cost per case of TB prevented for each
strategy compared to the base-case analysis but CE
ranking remained consistent.
Discussion
Our analysis indicates that use of IGRAs as a screening
tool, either alone or in conjunction with the TST, for
detecting LTBI is a more cost effective alternative than
using the TST alone. These results were consistent
regardless of which IGRA (T-SPOT.TB or QFT-GIT)
was used.
Dual screening, despite being less effective in terms of
active cases prevented, was less costly and consequently
more cost effective (in terms of incremental cost per TB
case prevented) than IGRA single screening. The T-
SPOT.TB dual strategy was actually found to be the
most cost effective option (£37,206 per case of active TB
prevented), followed very clo s e l yb yt h eQ F T - G I Td u a l
strategy, which, while cheaper than the T-SPOT.TB dual
strategy by £5,339, resulted in 0.18 more cases of active
TB. The T-SPOT.TB single strategy prevented the most
Table 6 Cost-effectiveness of screening strategies when cost estimates are varied in the sensitivity analysis.
Cost Variable Incremental cost per Active TB case prevented (British Pounds; £’s)
TST T-SPOT.TB QFT-GIT TST/T-SPOT.TB TST/QFT-GIT
Basecase Estimates £47,840
5# £39,712
3 £42,051
4 £37,206
1 £37,699
2
TST cost
£8.07 £45,249
5 £39,712
3 £42,051
4 £34,478
1 £34,788
2
£32.28 £53,024
5 £39,712
1 £42,051
2 £42,662
3 £43,523
4
T-SPOT.TB cost
£45.00 £47,840
5 £37,008
2 £42,051
4 £35,949
1 £37,699
3
£100.00 £47,840
4 £51,883
5 £42,051
2 £42,862
3 £37,699
1
QFT-GIT cost
£35.00 £47,840
5 £39,712
4 £39,166
3 £37,206
2 £36,358
1
£80.00 £47,840
4 £39,712
2 £52,147
5 £37,206
1 £42,395
3
Cost LTBI treatment
£262.30 £22,793
3 £23,542
4 £23,775
5 £21,036
2 £21,031
1
£1,049.18 £97,937
5 £72,053
3 £78,603
4 £69,547
1 £71,038
2
INH hepatitis
£314.56 £47,750
5 £39,654
3 £41,985
4 £37,148
1 £37,639
2
£1,258.24 £48,021
5 £39,829
3 £42,182
4 £37,322
1 £37,819
2
Post exposure TB
£3,809.84 £51,650
5 £43,522
3 £45,858
4 £41,016
1 £41,509
2
£15,239.34 £40,221
5 £32,093
3 £34,437
4 £29,586
1 £30,080
2
# The superscripts
1-5 indicate the cost-effectiveness ranking;
(1) indicates most cost effective strategy while
(5) indicates the least cost-effective strategy.
(LTBI - latent tuberculosis infection, TST - Tuberculin Skin Test, INH - isoniazid, QFT-GIT - Quantiferon-TB Gold-In-Tube)
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Page 9 of 14cases of post primary TB (3.70 cases) but was less cost-
effective than the T-SPOT.TB dual strategy as it cost
£41,596 more than the T-SPOT.TB dual strategy. Simi-
lar results were seen when QFT-GIT single and dual
strategies were compared.
Screening with T-SPOT.TB was more cost effective
than QFT-GIT screening when the dual (TST/QFT-GIT
vs. TST/T-SPOT.TB) and single (QFT-GIT vs. T-SPOT.
TB) strategies were directly compared. While the costs
incurred due to false positive and false negative results
were greater with the QFT-GIT based strategies (single
and dual), the higher test cost of the T-SPOT.TB
resulted in slightly higher overall costs of the T-SPOT.
TB single or dual strategies. This was offset by higher
effectiveness (fewer cases of post-exposure TB) resulting
from the T-SPOT.TB strategies.
Screening with TST alone had the lowest testing costs
(£15,433 per 1000 contacts), but incurred the highest
costs due to test inaccuracies (£70,081). While this strat-
egy prevented more cases of active TB than the dual
strategies (but not the single IGRA strategies), it had the
highest NNT (95.5) as over one third of the contacts
treated for LTBI would be false positives. As a result, it
was the least cost effective strategy.
Interpretation of the results will depend on the preva-
lence of infection, which within the UK and even within
districts of London varies widely [25]. Prevalence in the
screening group will also depend on the length of con-
tact and immigration status (high-incidence or low-inci-
dence), which may, in some part, explain why results of
some studies were different to ours [10,16]. If prevalence
is >52% then single testing with the T-SPOT.TB
becomes more cost effective than dual testing. The same
occurs with QFT-GIT screening when prevalence is
>59%. At this prevalence the TST also becomes more
cost effective than the dual strategies.
Overall our findings agree with recommendations by
NICE [7] for a sequential screening strategy using the
IGRA on all positive TSTs, despite different assumptions
on LTBI prevalence and test performance estimates. The
NICE cost-effectiveness analysis assumed that IGRAs
had equal sensitivity and only slightly higher specificity
than the TST, which may have reflected the relatively
small number of publications available on IGRAs at the
time this analysis was performed in 2004. Additionally,
the NICE cost effectiveness analysis assumed a much
lower prevalence of LTBI in contacts (8%). If we chan-
ged our estimates to equal those of the NICE analysis
(lower prevalence of LTBI, equal test sensitivities), our
findings still match those of the NICE analysis, that the
dual strategy (compared to an IGRA single strategy) is
the most cost-effective.
Other cost-effectiveness analyses investigating similar
populations and examining effectiveness in terms of
prevention of downstream active TB cases have drawn
similar conclusions to our study. Diel et al [9] using simi-
lar test performance estimates to our analysis, compared
similar strategies for the screening of close contacts using
the QFT assay and found the dual strategy to be more
cost-effective than the QFT single strategy. Oxlade et al
[12] concluded from a study comparing TST and QFT in
screening immigrants and contacts that a TST/QFT
strategy is more cost effective than QFT single screening,
particularly in a BCG vaccinated population.
Two studies have findings different to ours, supporting a
single IGRA testing strategy ahead of a dual screening
strategy. A Swiss study by Diel et al [10] found that T-
SPOT.TB single screening was more cost effective than
dual screening. However in this study cost effectiveness
was determined using total costs rather than incremental
costs. Using total cost outcomes from our study, we find
similar results to Diel’s study. Another Canadian study
[16] found QFT screening to be more cost effective than
TST/QFT screening in BCG vaccinated contacts when
incremental net monetary benefit was compared. If the
cost per TB case averted was compared then both strate-
gies were found to be dominant. Additionally, unlike our
study which compared each strategy to no screening, this
study compared each strategy to screening with TST only.
A significant factor in determining the CE rankings of
these strategies is the measure of cost effectiveness used.
Dual screening was more cost effective than single
screening when the incremental cost per case of active
TB was used as the cost effectiveness measure. However,
if total costs of a strategy rather than incremental costs
were considered to calculate the cost per TB case pre-
vented, single IGRA strategies were actually found to be
more cost effective than dual strategies. Regardless of
which measure is used, the TST only strategy remains
the least cost effective strategy.
To our knowledge, there have been no direct cost
comparisons between the two standardized versions of
the IGRAs. UK estimates of QFT-GIT costs are gener-
ally lower than the T-SPOT.TB as the latter is more
labour intensive and batch processing can greatly reduce
QFT-GIT test costs. However T-SPOT.TB remains
more cost-effective due to its seemingly superior test
performance over the QFT-GIT [4].
Although they were not included in the model, we
acknowledge that there are a number of other practical
issues that must be taken into consideration when
choosing a screening strategy (TST or IGRAs alone, or,
as part of a dual strategy). There is some early evidence
to suggest that using IGRAs for LTBI screening
increases compliance to INH treatment [26]. In our
model, better compliance would increase INH efficacy.
Subsequently, the IGRA single and dual strategies would
become even more cost effective.
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(assumed 100% TST return rate) [9,10,12,16] which in our
model, accounts for £6,622 per 1000 contacts screened
and results in 0.75 more cases of post primary TB. We
assumed that there will be a stringent follow up of con-
tacts thus we used a return rate of 90%. In reality, up to
60% of individuals fail to return for their TST results
[27,28]). At these lower return rates, single IGRA strate-
gies become more cost-effective than their dual strategy
counterparts. Thus, IGRAs increase the proportion of
individuals whose infection status is evaluable (LTBI or no
LTBI) and saves time and money wasted on chasing up
people to return for their TST to be read. Indeed, for this
reason, the Health Protection Agency in the UK [29]
recommends IGRA single testing in situations when
screening large numbers of individuals makes testing with
t h eT S Tp r o b l e m a t i cd u et ot h el a r g en u m b e ro fp e o p l e
that need to be followed up for TST reading. Nonetheless,
it must be recognized that IGRAs also have some logistical
problems. These include indeterminate results obtained
(~5% to 15% of assays [30-32] in some studies), patients’
refusal to have phlebotomy (8% in one recent study [28]),
difficulty in obtaining blood from children (17% in a study
in South Africa [33]), the need for additional phlebotomy
services, limitations imposed by cut-off times for specimen
transport, and patchy availability of these tests in the UK
due to cost constraints.
Some studies did not include drug-related toxicity in
their model [9,10,12]. Although isoniazid-associated
hepatotoxicity is uncommon, when it does occur, it is
difficult to treat and total costs are significant when
large numbers of individuals are offered chemoprophy-
laxis. For example in the USA, where there are an esti-
mated 350 000 treatment starts for LTBI annually (2002
estimate [34]), the total cost for treating isoniazid-asso-
ciated hepatotoxicity may be over $1 million dollars per
annum (assuming a hepatotoxicity risk of 0.3%). How-
ever when hepatitis rates were varied or even if excluded
from this analysis, incremental costs per active TB case
prevented only changed slightly but CE rankings
remained consistent showing that the choice of testing
strategy is insensitive to this variable.
The conclusion that is consistent in our study and pre-
vious cost analyses is that screening with the TST alone
is not cost effective compared to strategies using the
IGRA. However, whether IGRAs should be used as a
replacement to the TST or in conjunction with it remains
debatable. IGRA single screening does cost more (higher
testing costs) but less money is spent on false negatives.
Less false negatives means fewer people will progress to
active disease, resulting in these strategies being the most
effective (prevents most cases of post-primary TB). How-
ever the greater effectiveness of the single strategies does
not overcome the lower cost of the dual strategies when
incremental cost effectiveness is calculated.
Optimal choice of strategy will depend on logistical
constraints as discussed above, and the population being
screened as well as assumptions made in the costing
model. For example, TST sensitivity is impaired in an
immunocompromised population, such as HIV infected
patients [35,36]. IGRA single screening strategies will
undoubtedly be more suitable in this situation. Where
the cost or clinical consequences of treating active TB
are higher, such as with multi-drug resistant TB [37],
then the benefit of identifying and treating people in the
latent phase are even more pronounced, which may
favour an IGRA single strategy.
There are several limitations of this study. Our analysis
used a shorter timeframe of 2 years (other analyses used
Markov modeling over a 20 year period [9,10,12,15,16])
a n de x c l u d e dw i d e rt r a n s m i s s i o n .W eu s e dt h i st i m e -
frame as Markov modeling would have added consider-
able complexity to the model. Additionally, healthcare
institutions prefer to examine how implementation of a
new clinical intervention affects their annual budget
rather than long term overall costs over a 20 year period.
However, a shorter timeframe underestimates the num-
ber of downstream active TB cases. Thus the more effec-
tive strategies in our model (T-SPOT.TB and QFT-GIT
only) will become more cost effective if a longer time-
frame was used. Similarly wider transmission underesti-
mates the costs of less effective strategies. If included,
single IGRA strategies may become more cost-effective
as more future TB cases will be avoided. Nonetheless, it
is reassuring that the results of our model in terms of
ranking of the screening strategies are similar to analyses
that have included Markov processes [9].
Health assessment agencies typically use Quality of
Life Years (QALYs) as their outcome measure when
conducting cost-effectiveness analyses. Our analysis did
not include this measure due to limited UK data. Given
that the main source of quality of life losses is active TB
cases (as the risk of hepatitis is small) then strategies
which prevented the most active TB cases may become
more cost effective if QALYs were included. Addition-
ally, we only included costs from the narrow perspective
of the UK healthcare provider and did not include costs
to the wider society i.e. costs incurred on patients, costs
due to death, etc.
As there is no gold standard for detecting LTBI, data
on IGRA sensitivity and specificity are typically taken
from populations of active TB and healthy contacts,
respectively. Changes in these parameters can change
the CE rankings in our model. Consequently, more pro-
spective UK data on the performance of these IGRAs is
needed to better estimate these values.
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Page 11 of 14Other LTBI treatment regimens (3 months isoniazid
and rifampicin) have been recommended by the British
Thoracic Society [19] as alternatives to the currently used
6 months of INH. Furthermore, other countries, such as
the USA, recommend the use of either 9 months INH or
4 months of rifampicin for treating LTBI [38]. However
these effects are complex to model. Different regimens
will affect certain parameters in the model, including
effectiveness and costs of LTBI treatment, compliance
(shorter regimens will be tolerated better), risk of hepato-
toxicity and other adverse drug effects. Modeling these
different treatment regimens was beyond the scope of
this study but would be a fruitful area of future research.
Lastly, this model was constructed primarily to exam-
ine the consequences of screening contacts, which may
limit its applicability to other cohorts. Nonetheless, the
sensitivity analysis allows the results to be generalisable
across other cohorts, with changes in LTBI prevalence
and the risk of post-primary TB being key variables.
Conclusions
This study shows that, within the context of the
assumptions made, the TST/IGRA dual strategy is
cheaper than using T-SPOT.TB, or QFT-GIT or TST
alone, for the screening of TB contacts. While the T-
SPOT.TB and QFT-GIT alone prevent more cases of
active TB, this does not overcome the lower cost of the
dual strategies and consequently, using the measure of
incremental cost per case of TB prevented, then dual
strategies are more cost effective than their single IGRA
strategy counterparts. However, these conclusions are
dependent on the population being screened and on
assumptions made on the test performance of the
IGRAs compared to the TST. Nonetheless, using the
IGRA, whether in a single or dual strategy, is always
cheaper than using only the TST. This finding is very
insensitive to changes in variables within reasonable
parameters. These data should be considered when
selecting a suitable strategy for screening LTBI.
Additional file 1: Supplemental data. This section gives a brief
description of the structure of the decision tree model used in the cost
analysis, and also further explains the choice of the probability, cost
estimates and clinical effectiveness measures used in this analysis. This
document is in Microsoft Word 2003 format.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2466-10-7-
S1.DOC]
Acknowledgements
The authors would like to thank Anne Goodburn from the TB clinic,
University College London Hospitals and Fayaz Aziz for helpful suggestions
with the cost analysis. Keertan Dheda is supported by a SA NRF and DST
SARChI, and EU FP7 award.
Author details
1Centre for Infectious Diseases and International Health, Division of Infection
and Immunity, University College London Medical School, University College
London, 43 Cleveland Street, London, W1T 4JF, UK.
2TB Clinic, University
College London Hospitals NHS Trust, London, WC1E 6AU, UK.
3Department
of Population Sciences and Primary Care, University College London Medical
School, University College London, London, WC1E 6JB, UK.
4Division of
Pulmonology and UCT Lung Institute, Department of Medicine, University of
Cape Town & Groote Schuur Hospital, Observatory Cape Town, 7925, South
Africa.
5Institute of Infectious Diseases and Molecular Medicine, University of
Cape Town, South Africa.
Authors’ contributions
AP was involved with data acquisition, performing the cost analysis and
drafting and critical review of the manuscript; RFM helped with the study
design, data acquisition and manuscript drafting; HB, JH, GS, AZ and GR
were all involved in study design, data acquisition, analysis and drafting of
the manuscript; MB was involved in analysis of data and manuscript revision;
KD supervised the overall study design, data acquisition, analysis, manuscript
drafting and final submission. All authors contributed to the manuscript and
gave approval for final submission.
Competing interests
The authors declare that they have no competing interests.
Received: 6 November 2008
Accepted: 22 February 2010 Published: 22 February 2010
References
1. Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA: Utility of the
antigen-specific interferon-gamma assay for the management of
tuberculosis. Curr Opin Pulm Med 2005, 11(3):195-202.
2. Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis
of latent tuberculosis infection: areas of uncertainty and
recommendations for research. Annals of internal medicine 2007,
146(5):340-354.
3. Pai M, Riley LW, Colford JM Jr: Interferon-gamma assays in the
immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis
2004, 4(12):761-776.
4. Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based assays for
the diagnosis of latent tuberculosis infection: an update. Annals of
internal medicine 2008, 149(3):177-184.
5. Farhat M, Greenaway C, Pai M, Menzies D: False-positive tuberculin skin
tests: what is the absolute effect of BCG and non-tuberculous
mycobacteria?. Int J Tuberc Lung Dis 2006, 10(11):1192-1204.
6. Lalvani A: Diagnosing tuberculosis infection in the 21st century: new
tools to tackle an old enemy. Chest 2007, 131(6):1898-1906.
7. National Institute for Health and Clinical Excellence: Clinical diagnosis and
management of tuberculosis, and measures for its prevention and
control: Clinical Guideline 33. 2006http://guidance.nice.org.uk/CG33/
costreport/.
8. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A:
Guidelines for using the QuantiFERON-TB Gold test for detecting
Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep
2005, 54(RR-15):49-55.
9. Diel R, Nienhaus A, Loddenkemper R: Cost-effectiveness of interferon-
gamma release assay screening for latent tuberculosis infection
treatment in Germany. Chest 2007, 131(5):1424-1434.
10. Diel R, Wrighton-Smith P, Zellweger JP: Cost-effectiveness of interferon-
gamma release assay testing for the treatment of latent tuberculosis. Eur
Respir J 2007, 30(2):321-332.
11. Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A: Enhanced cost-
benefit analysis of strategies for LTBI screening and INH
chemoprevention in Germany. Respiratory medicine 2009,
103(12):1838-1853.
12. Oxlade O, Schwartzman K, Menzies D: Interferon-gamma release assays
and TB screening in high-income countries: a cost-effectiveness analysis.
Int J Tuberc Lung Dis 2007, 11(1):16-26.
13. Wrighton-Smith P, Zellweger JP: Direct costs of three models for the
screening of latent tuberculosis infection. Eur Respir J 2006, 28(1):45-50.
Pooran et al. BMC Pulmonary Medicine 2010, 10:7
http://www.biomedcentral.com/1471-2466/10/7
Page 12 of 1414. Diel R, Nienhaus A, Lange C, Schaberg T: Cost-optimisation of screening
for latent tuberculosis in close contacts. Eur Respir J 2006, 28(1):35-44.
15. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH: Cost-
effectiveness of interferon gamma release assays vs tuberculin skin tests
in health care workers. Archives of internal medicine 2009, 169(2):179-187.
16. Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, Elwood RK,
Morshed M, Brunham RC, Fitzgerald JM: Cost-effectiveness of a new
interferon-based blood assay, QuantiFERON-TB Gold, in screening
tuberculosis contacts. Int J Tuberc Lung Dis 2008, 12(12):1414-1424.
17. Taylor WC, Aronson MD, Delbanco TL: Should young adults with a
positive tuberculin test take isoniazid?. Annals of internal medicine 1981,
94(6):808-813.
18. Bank of England: Consumer Price Inflation Calculator, 1750 to 2008.http://
www.bankofengland.co.uk/education/inflation/calculator/index1.htm.
19. Control and Prevention of Tuberculosis in the United Kingdom: Code of
practice 2000. Thorax 2000, 887-901.
20. Schwartzman K, Menzies D: Tuberculosis screening of immigrants to low-
prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care
Med 2000, 161(3 Pt 1):780-789.
21. Thompson NP, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW,
Burroughs AK, McIntyre N: Anti-tuberculosis medication and the liver:
dangers and recommendations in management. Eur Respir J 1995,
8(8):1384-1388.
22. Weiseger RA: Isoniazid Hepatotoxicity. 2007http://www.emedicine.com/
med/topic1193.htm.
23. Efficacy of various durations of isoniazid preventive therapy for
tuberculosis: five years of follow-up in the IUAT trial. International Union
Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ
1982, 60(4):555-564.
24. Tsevat J, Taylor WC, Wong JB, Pauker SG: Isoniazid for the tuberculin
reactor: take it or leave it. Am Rev Respir Dis 1988, 137(1):215-220.
25. Health Protection Agency: Tuberculosis in the UK: Annual report on
tuberculosis surveillance in the UK 2009.http://www.hpa.org.uk/web/
HPAwebFile/HPAweb_C/1259152022594.
26. Sahni R, Miranda C, Yen-Lieberman B, Tomford JW, Terpeluk P, Quartey P,
Johnson LT, Gordon SM: Does the implementation of an interferon-
gamma release assay in lieu of a tuberculin skin test increase
acceptance of preventive therapy for latent tuberculosis among
healthcare workers?. Infect Control Hosp Epidemiol 2009, 30(2):197-199.
27. Bothamley GH, Rowan JP, Griffiths CJ, Beeks M, McDonald M, Beasley E,
Bosch van den C, Feder G: Screening for tuberculosis: the port of arrival
scheme compared with screening in general practice and the homeless.
Thorax 2002, 57(1):45-49.
28. Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura LM:
Feasibility, acceptability, and cost of tuberculosis testing by whole-blood
interferon-gamma assay. BMC Infect Dis 2006, 6:47.
29. HPA Tuberculosis Program Board: Health Protection Agency position
statement on the use of Interferon Gamma Release Assay (IGRA) tests
for Tuberculosis (TB): Interim HPA guidance. 2008http://www.hpa.org.uk/
web/HPAwebFile/HPAweb_C/1214808549127.
30. Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M, Meccugni B,
Dori IM, Andreani A, Bergamini BM, et al: Use in routine clinical practice of
two commercial blood tests for diagnosis of infection with
Mycobacterium tuberculosis: a prospective study. Lancet 2006,
367(9519):1328-1334.
31. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K,
Shigeto E, Harada N, Mitarai S, Okada M, et al: Specific detection of
tuberculosis infection: an interferon-gamma-based assay using new
antigens. Am J Respir Crit Care Med 2004, 170(1):59-64.
32. Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, Kok-
Jensen A, Andersen P, Weldingh K: Prospective evaluation of a whole-
blood test using Mycobacterium tuberculosis-specific antigens ESAT-6
and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol
2005, 12(4):491-496.
33. Tsiouris SJ, Austin J, Toro P, Coetzee D, Weyer K, Stein Z, El-Sadr WM:
Results of a tuberculosis-specific IFN-gamma assay in children at high
risk for tuberculosis infection. Int J Tuberc Lung Dis 2006, 10(8):939-941.
34. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR: The
scope and impact of treatment of latent tuberculosis infection in
the United States and Canada. Am J Respir Crit Care Med 2006,
173(8):927-931.
35. Dheda K, Lalvani A, Miller R, Scott G, Booth H, Johnson M, Zumla A, Rook G:
Performance of a T-cell-based diagnostic test for tuberculosis infection
in HIV-infected individuals is independent of CD4 cell count. AIDS 2005,
19:2038-2041.
36. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A: Diagnosis
of tuberculosis in South African children with a T-cell-based assay: a
prospective cohort study. Lancet 2004, 364(9452):2196-2203.
37. White VL, Moore-Gillon J: Resource implications of patients with
multidrug resistant tuberculosis. Thorax 2000, 55(11):962-963.
38. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM,
Peloquin CA, Gordin FM, Nunes D, Strader DB, et al: An official ATS
statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit
Care Med 2006, 174(8):935-952.
39. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P,
Lalvani A: Comparison of T-cell-based assay with tuberculin skin test for
diagnosis of Mycobacterium tuberculosis infection in a school
tuberculosis outbreak. Lancet 2003, 361(9364):1168-1173.
40. Shams H, Weis SE, Klucar P, Lalvani A, Moonan PK, Pogoda JM, Ewer K,
Barnes PF: Enzyme-linked immunospot and tuberculin skin testing to
detect latent tuberculosis infection. Am J Respir Crit Care Med 2005,
172(9):1161-1168.
41. Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP,
Pasvol G, Hill AV: Rapid detection of Mycobacterium tuberculosis
infection by enumeration of antigen-specific T cells. Am J Respir Crit Care
Med 2001, 163(4):824-828.
42. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T: Sensitivity
of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for
diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis
2005, 24(8):529-536.
43. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G,
Hill AV, Lalvani A: Direct ex vivo analysis of antigen-specific IFN-gamma-
secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals:
associations with clinical disease state and effect of treatment. J
Immunol 2001, 167(9):5217-5225.
44. Goletti D, Vincenti D, Carrara S, Butera O, Bizzoni F, Bernardini G,
Amicosante M, Girardi E: Selected RD1 peptides for active tuberculosis
diagnosis: comparison of a gamma interferon whole-blood enzyme-
linked immunosorbent assay and an enzyme-linked immunospot assay.
Clin Diagn Lab Immunol 2005, 12(11):1311-1316.
45. Huebner RE, Schein MF, Bass JB Jr: The tuberculin skin test. Clin Infect Dis
1993, 17(6):968-975.
46. Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh Y, Kim WS,
Kim DS, et al: Comparison of two commercial interferon-gamma assays
for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006,
28(1):24-30.
47. Taylor Z: The cost-effectiveness of screening for latent tuberculosis
infection. Int J Tuberc Lung Dis 2000, 4(12 Suppl 2):S127-133.
48. Bass JB Jr, Farer LS, Hopewell PC, O’Brien R, Jacobs RF, Ruben F, Snider DE
Jr, Thornton G: Treatment of tuberculosis and tuberculosis infection in
adults and children. American Thoracic Society and The Centers for
Disease Control and Prevention. Am J Respir Crit Care Med 1994,
149(5):1359-1374.
49. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM: Isoniazid for preventing
tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev
2000, , 2: CD001363.
50. Steele MA, Burk RF, DesPrez RM: Toxic hepatitis with isoniazid and
rifampin. A meta-analysis. Chest 1991, 99(2):465-471.
51. Salpeter SR: Fatal isoniazid-induced hepatitis. Its risk during
chemoprophylaxis. West J Med 1993, 159(5):560-564.
52. Salpeter SR, Salpeter EE: Screening and treatment of latent tuberculosis
among healthcare workers at low, moderate, and high risk for
tuberculosis exposure: a cost-effectiveness analysis. Infect Control Hosp
Epidemiol 2004, 25(12):1056-1061.
53. Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis. A general
review. Bibl Tuberc 1970, 26:28-106.
54. Comstock GW: How much isoniazid is needed for prevention of
tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis
1999, 3(10):847-850.
55. Dasgupta K, Menzies D: Cost-effectiveness of tuberculosis control
strategies among immigrants and refugees. Eur Respir J 2005,
25(6):1107-1116.
Pooran et al. BMC Pulmonary Medicine 2010, 10:7
http://www.biomedcentral.com/1471-2466/10/7
Page 13 of 1456. UK Department of Health: National tariff 2005-06.http://www.dh.gov.uk/en/
Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/
DH_4091529.
57. Curtis L: Unit costs of health and social care 2007.http://www.pssru.ac.uk/
pdf/uc/uc2007/uc2007.pdf.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2466/10/7/prepub
doi:10.1186/1471-2466-10-7
Cite this article as: Pooran et al.: Different screening strategies (single or
dual) for the diagnosis of suspected latent tuberculosis: a cost
effectiveness analysis. BMC Pulmonary Medicine 2010 10:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pooran et al. BMC Pulmonary Medicine 2010, 10:7
http://www.biomedcentral.com/1471-2466/10/7
Page 14 of 14